Keros Therapeutics (KROS)
(Delayed Data from NSDQ)
$45.06 USD
-0.31 (-0.68%)
Updated Aug 28, 2024 04:00 PM ET
After-Market: $44.93 -0.13 (-0.29%) 7:16 PM ET
3-Hold of 5 3
F Value F Growth A Momentum F VGM
Brokerage Reports
0 items in cart
Keros Therapeutics, Inc. [KROS]
Reports for Purchase
Showing records 21 - 40 ( 52 total )
Company: Keros Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
Company: Keros Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
Positive on KER-050 MDS/MF Data Update in 2H23; KER-012 Update on 8/8; Reit Buy and $100 PT
Provider: H.C. Wainwright & Co., Inc.
Analyst: FEIN A
Company: Keros Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
Q2: Ph2 KER-012/PAH Trial Design Call on 8/8 at 8AM ET; Pipeline Progress
Provider: Wedbush Securities Inc.
Analyst: ARGYRIDES A
Company: Keros Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
Company: Keros Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
Company: Keros Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
Building Best-in-Class TGF-a Signaling Pathway Modulators; Initiate OP $86 PT
Provider: Wedbush Securities Inc.
Analyst: ARGYRIDES A
Company: Keros Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
Company: Keros Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
Rich Data Updates Across Pipeline Reinforce Standout Plays in MDS, MF and PAH; Reit. Buy and $100 PT
Provider: H.C. Wainwright & Co., Inc.
Analyst: FEIN A
Company: Keros Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
Rich Pipeline Progress; Sotatercept Data At ACC Potentially Can Highlight Strengths of KER-012; Reit. Buy and $100 PT
Provider: H.C. Wainwright & Co., Inc.
Analyst: FEIN A
Company: Keros Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
Clinical Updates From KER-050 and KER-047 Continue to Build on Positive Clinical Profiles
Provider: H.C. Wainwright & Co., Inc.
Analyst: FEIN A
Company: Keros Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
Initial and Expanding Data For KER-047 and KER-050, by YE22; Reit Buy and $100 PT
Provider: H.C. Wainwright & Co., Inc.
Analyst: FEIN A
Company: Keros Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
Positive KER-012 Update Points to a Differentiated Asset Against Bone Loss; Reit. Buy and $100 PT
Provider: H.C. Wainwright & Co., Inc.
Analyst: FEIN A
Company: Keros Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
A Data Rich 2H22, Plans to Showcase Keros? Entire Pipeline Across Multiple Indications; Reit Buy and $100 PT
Provider: H.C. Wainwright & Co., Inc.
Analyst: FEIN A
Company: Keros Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
Positive MDS Update at EHA; Continues to Build Momentum For KER-050
Provider: H.C. Wainwright & Co., Inc.
Analyst: FEIN A
Company: Keros Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
KER-012 Phase 1 Healthy Volunteer Data Bodes Well For Development in PAH and Bone Disorders
Provider: H.C. Wainwright & Co., Inc.
Analyst: FEIN A
Company: Keros Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
Positive Ahead of Phase 2 MDS Update in Mid-22; Reit Buy and $100 PT
Provider: H.C. Wainwright & Co., Inc.
Analyst: FEIN A
Company: Keros Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
Strong Momentum From KER-050 Expected to Continue Throughout 2022; Reit. Buy and $100 PT
Provider: H.C. Wainwright & Co., Inc.
Analyst: FEIN A
Company: Keros Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
KER-050 Continues to Gain Momentum in MDS at ASH 2021
Provider: H.C. Wainwright & Co., Inc.
Analyst: FEIN A
Company: Keros Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
KER-050 Reports Positive Update During ASH 2021; Reit Buy and $100 PT
Provider: H.C. Wainwright & Co., Inc.
Analyst: FEIN A